EN | 中文
Napo Pharmaceuticals

Napo Pharmaceuticals focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. On December 31, 2012, FDA approved FulyzaqTM (crofelemer) for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. The botanical drug substance of FulyzaqTM is extracted from Croton lechleri that is harvested from the wild in South America.